Company Analysis ADC Therapeutics SA
1. Summary
Advantages
- The stock's return over the last year (37.29%) is higher than the sector average (-31.08%).
- The company's current efficiency (ROE=89.97%) is higher than the sector average (ROE=-73.93%)
Disadvantages
- Price (4.05 $) is higher than fair price (3.85 $)
- Dividends (0%) are below the sector average (1.35%).
- Current debt level 38.2% has increased over 5 years from 3.63%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ADC Therapeutics SA | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.6% | 3.5% | 0.3% |
| 90 days | 29.4% | -21.8% | 3.6% |
| 1 year | 37.3% | -31.1% | 14.1% |
ADCT vs Sector: ADC Therapeutics SA has outperformed the "Healthcare" sector by 68.37% over the past year.
ADCT vs Market: ADC Therapeutics SA has outperformed the market by 23.16% over the past year.
Stable price: ADCT is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ADCT with weekly volatility of 0.7171% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (4.05 $) is higher than the fair price (3.85 $).
Price is higher than fair: The current price (4.05 $) is 4.9% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-1.81) is lower than that of the sector as a whole (27.88).
P/E vs Market: The company's P/E (-1.81) is lower than that of the market as a whole (56.03).
5.3. P/BV
P/BV vs Sector: The company's P/BV (-0.9541) is lower than that of the sector as a whole (10.22).
P/BV vs Market: The company's P/BV (-0.9541) is lower than that of the market as a whole (17.56).
5.5. P/S
P/S vs Sector: The company's P/S indicator (2.79) is lower than that of the sector as a whole (4.09).
P/S vs Market: The company's P/S indicator (2.79) is lower than that of the market as a whole (27.86).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.6314) is lower than that of the sector as a whole (18.11).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.6314) is lower than that of the market as a whole (32.46).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -7.18% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-7.18%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.2891%).
6.4. ROE
ROE vs Sector: The company's ROE (89.97%) is higher than that of the sector as a whole (-73.93%).
ROE vs Market: The company's ROE (89.97%) is higher than that of the market as a whole (38.94%).
6.6. ROA
ROA vs Sector: The company's ROA (-46.65%) is lower than that of the sector as a whole (6.84%).
ROA vs Market: The company's ROA (-46.65%) is lower than that of the market as a whole (11.33%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-55.09%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (-55.09%) is lower than that of the market as a whole (10.1%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.35%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
